Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cynata Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Alive and Kicking: Watch this space on controversy-free stem-cell therapy trials, says Cynata
Health & Biotech
ASX Health Stocks: Big tick for Cynata’s stem-cell therapy
Health & Biotech
ASX Health Stocks: Imricor installs key equipment at Swiss hospital
Health & Biotech
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
Tech
From high-tech cancer fighters to AI-wielding crime busters, these are some of the most innovative firms on the ASX
Tech
Up close and personal with ASX tech and Biotech
News
Hot Money Monday: The Simple Moving Average chart, and how it’s used to profit from a stock’s upward trend
Health & Biotech
ASX Health Stocks: Healius rips higher as new CEO takes over; Nova Eye bags record US sales
Health & Biotech
ASX Health Stocks: Recce, Cynata say their diabetic foot ulcer trials are going great guns
News
ASX Small Caps Lunch Wrap: Is the world ready for a terrifying hybrid stingray shark?
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX phones in more gains as prices plunge in Beijing and records tumble in New York
Health & Biotech
ASX Health Stocks: More positive data for Recce’s drug, Cynata expects trial results in Q1
Health & Biotech
ASX Health Stocks: Althea says its cannabis beverage could generate $5m of sales in Canada
Health & Biotech
ASX Health Stocks: Medibio jumps 50pc on Phase 1 results; Cann doubles cannabis harvest
Experts
Dr Boreham’s Crucible: Is this a case of what’s good for Mesoblast is good for Cynata?
News